CRISPR and CAS Gene Technology Market Size & Share, by Products (Enzymes, Kits, Libraries), Services (gRNA Design, Cell Line Engineering), Application (Biomedical, Agricultural, Industrial, Biological Research) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3287
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

CRISPR And CAS Gene Technology Market size was over USD 4.85 billion in 2024 and is likely to cross USD 33.05 billion by the end of 2037, witnessing more than 20.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of CRISPR and CAS gene technology is estimated at USD 5.65 billion. The growth of the market can be attributed to the increasing applications in biotechnology, agriculture, the food industry, medicine, and gene technology. Genetic engineering is the most popular segment that is used in the production of therapeutic proteins and drugs. The increasing advancements in the research of biotechnology enhance the applications in human health directly or indirectly and are estimated to drive market growth. The biotechnology sector in India was estimated to cross over USD 80.12 billion with a growth rate of 14% as per the data of Invest India in 2022.

In addition to these, rising investment opportunities in the biotechnology sector for the production of diagnostics, therapeutics, and vaccines are expected to have a positive impact on market growth across the world. The increasing government initiatives and investments in the discovery of biosimilars to reduce the cost of the healthcare sector in low and middle-income countries are also propelling market growth in the coming years. As per the observations in 2022, biosimilars in the U.S. are projected to reduce drug expenditure by USD 130 billion by 2025. Biosimilars are complex molecules that are manufactured in living cells that are highly similar to the reference product with less variation.


CRISPR and CAS Gene Technology Market overview
Get more information on this report: Request Free Sample PDF

CRISPR and CAS Gene Technology Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Applications of CRISPR and CAS Gene Technology in Various Fields -

The increasing number of diseases such as HIV, sickle cell disease, transthyretin amyloidosis, and other disorders that affect the immune system and genes of the body is estimated to drive market growth. The increasing use of genetic engineering techniques to modify defective genes is propelling market growth during the forecast period.

As per the Centers for Disease Control and Prevention, in 2020 about 30,635 people in the U.S. were diagnosed with HIV.

  • Increasing Government and Private Funding for Medical Research – The National Institutes of Health (NIH) invested most of its budget which is USD 45 billion in medical research activities for Americans in 2021 and it was reported that 2 billion is spent on medical research by NIH every year.
  • Rising Incidence of Genetic Abnormalities in Humans for Various Reasons – The total number of cases of dengue in America between 1st and 2nd epidemiological week in 2022 was estimated to be over 3,120,350 cases.
  • Growing Food Crisis across the World with Rising Urbanization – The Department of Biotechnology in India funded 51 Biotech-Kisan hubs for the farmers to connect them with well-experienced scientists and institutions according to Invest India. As of 2022 data, 44 of 51 operational hubs are situated in 15 Agro-climatic zones of the nation and conduct operations in an overall 169 districts in India.
  • Increasing Cancer Cases with Gene Mutations Caused by UV radiation and Hydrofluorocarbons in Air – More than 300, 580 new breast cancer cases are projected to rise in the United States by the end of 2023.

Challenges

  • Pending Patent Concerns & Outcomes of Clinical Trials Associated with the Technology
  • Ethical Concern on Genetically Modified Foods and Organisms by CRISPR and CAS gene technology – The generation of these genetically modified foods and changes in the organisms is ethically not safe as it alters the germline of humans which is estimated to hamper the market growth. The CRISPR gene technology is to treat the mutated genes in patients to treat diseases that alter the natural DNA sequence of humans which is considered immoral is hampering the market growth.
  • Requirement for Professionals, High Cost of Investment, and Time Consumption

CRISPR and CAS Gene Technology Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

20.4%

Base Year Market Size (2024)

USD 4.85 billion

Forecast Year Market Size (2037)

USD 33.05 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

CRISPR and CAS Gene Technology Segmentation

Application (Biomedical, Agricultural, Industrial, Biological Research)

The market is also segmented and analyzed for demand and supply by application into biomedical, agricultural, industrial, biological research, and others. Amongst these segments, the biomedical segment is expected to garner a significant share of around 32% in the year 2037. The CRISPR/dCas9 systems are used in the biological and biomedical fields for gene therapy, genome screening, genome editing, live-cell imaging, and cancer study. The increasing use in the detection of the presence of viral infections such as Zika virus, dengue virus, influenza A H7H9, and hepatitis is estimated to drive the market segment growth during the forecast period as per the market analysis. The Zika virus transmitted to more than 40,000 persons in 2022 during epidemiological weeks 1 and 2 in regions of America that included 15 of 52 countries and territories.

The global CRISPR and CAS gene technology market is segmented and analyzed for demand and supply by application into biomedical, agricultural, industrial, biological research, and others. Out of these segments, the agricultural segment is estimated to gain the largest market share of about 23% in the year 2037. The growth of the segment can be attributed to the increasing applications in agriculture to improve quantity and quality of yield. The growing demand for pest-resistant and climate-adaptable crops to prevent food scarcity in low-income countries is estimated to drive the market segment growth. The use of CRISPR and CAS gene technology in agricultural crops helps to enhance the plant yield and increase the resistance to diseases, and herbicides, and accelerate domestication. The increasing gene manipulation of plants to create a plant with beneficial traits and develop a novel and more sustainable crop plant for agricultural systems.

Our in-depth analysis of the global market includes the following segments:

       By Products & Services

  • Products
    • Enzymes
    • Kits
    • Libraries
    • Others
  • Services
    • gRNA Design
    • Cell Line Engineering
    • Others

 

         By Application

  • Biomedical
  • Agricultural
  • Industrial
  • Biological Research
  • Others

 


Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

CRISPR and CAS Gene Technology Regional Synopsis

North American Market Forecast

The market share of CRISPR and CAS gene technology in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 37% by the end of 2037. The growth of the market can be attributed majorly to the increasing growing investment of governmental and non-governmental agencies in R&D activities regarding CRISPR and CAS gene technology, accompanied by the presence of leading pharma & biotech companies and their early adoption of CRISPR technology. Along with this, North America also leads in terms of ongoing clinical trials, which is also expected to contribute to the market growth in the region. The increasing number of key players in the region investing the gene technology to improve biosimilars and biomedical drugs is estimated to hike the market growth. Many new biosimilars are developed in the U.S. for existing drugs. For instance, in 2019 Mvasi made by Amgen, and in 2020 Zirabev made by Pfizer are biosimilars approved by U.S. Food and Drug Administration for Avastin which is a Genetech product. Similarly, the Lantus of Sanofi has Semglee and Basaglar which are biosimilars from Viatris and Eli Lily companies developed in 2020.

APAC Market Statistics

The Asia Pacific CRISPR and CAS gene technology market is estimated to be the second largest, registering a share of about 24% by the end of 2037. The growth of the market can be attributed majorly to the rising investments in CRISPR and CAS gene technology and increasing research collaborations between universities and biotech companies in the region. Along with this, the Asia Pacific region has an increasing prevalence of chronic disorders, which is also expected to drive market growth in the region. The growing importance of agriculture owing to the rising population in the region is projected to increase the growth opportunities of the market in the region. The presence of gene mutations in people working in mining and chemical industries as well as pharmaceuticals for a longer time is estimated to drive market growth. The increasing need for healthcare expenditure in the region with the rising prevalence of many genetic disorders owing to a lack of awareness of people is propelling the market growth.

Europe Market Forecast

Further, the market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the increased research expenditure related to CRISPR technology. As per a report published by European Parliamentary Research Service in 2020, crops edited using CRISPR and CAS gene technology may become a part of a transition to a more sustainable form of agriculture. Rising investments in gene editing-based research and development with the introduction of several applications are estimated to propel the market growth in the coming years. The rising concern by medical professionals in the region to prevent the spread of chronic illnesses that cannot be cured with medical treatment is estimated to propel the growth of the CRISPR and CAS gene technology market. The rising demand for cell line engineering services with increasing government investments to rise the healthcare of the people in the region is fueling the market growth.

Research Nester
CRISPR and CAS Gene Technology Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the CRISPR and CAS Gene Technology Landscape

    • Thermo Fisher Scientific Holdings, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Origene Technologies
    • Addgene, Inc.
    • Merck KGaA
    • GenScript Biotech
    • Cellecta, Inc.
    • Caribou Bioscience, Inc.
    • Horizon Discovery Group
    • Mammoth Biosciences, Inc.
    • Inscripta, Inc.

In the News

  • GenScript Biotech entered into an agreement with InnoBation Co. Ltd. for the cell line development and engineering of GMP plasmids and lentivirus. Through this agreement, GenScript is aiming to provide CRO services to InnoBation by using CRISPR and CAS gene technology.
  • University of Connecticut Health Center developed “All-In-One Dual CRISPR-Cas 12a (AIOD-CRISPR)” assay method, which performs ultrasensitive, specific, and visual detection of nucleic acid in the SARS-COV-2 virus and can test for COVID-19 infection at a quicker pace.
  • Mammoth Biosciences, Inc. developed a new CRISPR technology-based test for COVID- 19 detections called “SARS-COV-2 DETECTR”, which can take out results within an hour of the test using loop-mediated amplification and CAS12 enzyme.

Author Credits:  Radhika Pawar


  • Report ID: 3287
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of CRISPR and CAS gene technology is estimated at USD 5.65 billion.

The CRISPR and CAS gene technology market size was over USD 4.85 billion in 2024 and is likely to cross USD 33.05 billion by the end of 2037, witnessing more than 20.4% CAGR during the forecast period i.e., between 2025-2037. The rising applications of CRISPR and CAS gene technology and the increasing government and private funding for medical research will impel the market growth.

North American industry is projected to have the highest growth through 2037, led by increasing investment of governmental and non-governmental agencies in R&D activities.

The major players in the market include Thermo Fisher Scientific Holdings, Inc., Origene Technologies, Addgene, Inc., Merck KGaA, GenScript Biotech, Cellecta, Inc., Caribou Bioscience, Inc., Horizon Discovery Group, Mammoth Biosciences, Inc., Inscripta, Inc.
CRISPR and CAS Gene Technology Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample